Ketorolac is a potent non-steroidal anti-inflammatory drug (NSAID) that can inhibit cyclooxygenase activity and prostaglandin synthesis, thereby reducing pain and inflammation. The aim of this study was to investigate the hepatorenal toxicity of ketorolac administration in adult male rats. Twenty-four adult male Wistar rats were randomly assigned to three groups (n = 8 per group): a control group receiving normal saline (1 mL/kg), a low-dose ketorolac group (10 mg/kg), and a high-dose ketorolac group (20 mg/kg). The animals were maintained under standard housing conditions for three weeks after the last treatment. Blood samples were collected under anesthesia, and serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine (Cr) were measured using commercial kits and a BT 1000 Biotectica analyzer. Compared to the control group, the low-dose ketorolac group did not show a significant increase in ALT and AST levels, but the high-dose ketorolac group exhibited a significant elevation in these hepatic enzymes (P < 0.05). Both the low-dose and high-dose ketorolac groups demonstrated a significant increase in BUN and Cr levels compared to the control group, with the high-dose group showing a more pronounced elevation in these renal parameters (p < 0.05). The findings of this study suggest that high-dose ketorolac administration can induce hepatotoxic and nephrotoxic effects, as evidenced by the increased levels of liver and kidney function markers in adult male rats. These results highlight the importance of careful monitoring and dose optimization when using ketorolac in clinical settings.
References
1.
BRATER D. Anti-inflammatory agents and renal function☆, ☆☆. Seminars in Arthritis and Rheumatism. 2002;32(3):33–42.
2.
Lacroix I, Lapeyre‐Mestre M, Bagheri H, Pathak A, Montastruc JL. Nonsteroidal anti‐inflammatory drug‐induced liver injury: a case–control study in primary care. Fundamental & Clinical Pharmacology. 2004;18(2):201–6.
Soleimanpour M, Imani F, Safari S, Sanaie S, Soleimanpour H, Ameli H, et al. The Role of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the Treatment of Patients With Hepatic Disease: A Review Article. Anesthesiology and Pain Medicine. 6(4).
5.
Rubenstein JH, Laine L. The hepatotoxicity of non‐steroidal anti‐inflammatory drugs. Alimentary Pharmacology & Therapeutics. 2004;20(4):373–80.
6.
Aithal GP, Day CP. Nonsteroidal Anti-Inflammatory Drug–Induced Hepatotoxicity. Clinics in Liver Disease. 2007;11(3):563–75.
7.
Ingrasciotta Y, Sultana J, Giorgianni F, Fontana A, Santangelo A, Tari DU, et al. Association of Individual Non-Steroidal Anti-Inflammatory Drugs and Chronic Kidney Disease: A Population-Based Case Control Study. PLOS ONE. 10(4):e0122899.
8.
Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. European Journal of Internal Medicine. 2015;26(4):285–91.
9.
Lafrance J, Miller DR. Selective and non‐selective non‐steroidal anti‐inflammatory drugs and the risk of acute kidney injury. Pharmacoepidemiology and Drug Safety. 2009;18(10):923–31.
10.
Hörl WH. Nonsteroidal Anti-Inflammatory Drugs and the Kidney. Pharmaceuticals. 3(7):2291–321.
11.
Galli G, Panzetta G. Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient. G Ital Nefrol. 2002;19:199–203.
12.
Donati M, Conforti A, Lenti MC, Capuano A, Bortolami O, Motola D, et al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy. British Journal of Clinical Pharmacology. 2016;82(1):238–48.
13.
Dixit M, Doan T, Kirschner R, Dixit N. Significant Acute Kidney Injury Due to Non-steroidal Anti-inflammatory Drugs: Inpatient Setting. Pharmaceuticals. 3(4):1279–85.
14.
PERAZELLA MA, BULLER GK. NSAID Nephrotoxicity Revisited: Acute Renal Failure Due to Parenteral Ketorolac. Southern Medical Journal. 1993;86(12):1421–4.
15.
Drożdżal S, Lechowicz K, Szostak B, Rosik J, Kotfis K, Machoy‐Mokrzyńska A, et al. Kidney damage from nonsteroidal anti‐inflammatory drugs—Myth or truth? Review of selected literature. Pharmacology Research & Perspectives. 2021;9(4).
16.
Hall ST, Mangram AJ, Barletta JF. Identification of Risk Factors for Acute Kidney Injury from Intravenous Ketorolac in Geriatric Trauma Patients. World Journal of Surgery. 2022;46(1):98–103.
17.
AITKEN HA, BURNS JW, MCARDLE CS, KENNY GNC. EFFECTS OF KETOROLAC TROMETAMOL ON RENAL FUNCTION. British Journal of Anaesthesia. 1992;68(5):481–5.
18.
David Waterbury L, Silliman D, Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Current Medical Research and Opinion. 2006;22(6):1133–40.
19.
Takahashi K, Patel AK, Nagai S, Safwan M, Putchakayala KG, Kane WJ, et al. Perioperative Ketorolac Use: A Potential Risk Factor for Renal Dysfunction After Live-Donor Nephrectomy. Annals of Transplantation. 22:563–9.
20.
Freedland SJ, Blanco-Yarosh M, Sun JC, Hale SJ, Elashoff DA, Rajfer J, et al. Effect of ketorolac on renal function after donor nephrectomy. Urology. 2002;59(6):826–30.
Macario A, Lipman AG. Ketorolac in the Era of Cyclo-Oxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Efficacy, Side Effects, and Regulatory Issues. Pain Medicine. 2001;2(4):336–51.
23.
Domínguez-Oliva A, Hernández-Ávalos I, Martínez-Burnes J, Olmos-Hernández A, Verduzco-Mendoza A, Mota-Rojas D. The Importance of Animal Models in Biomedical Research: Current Insights and Applications. Animals. 13(7):1223.
24.
Marzuillo P, Calligaris L, Amoroso S, Barbi E. Narrative review shows that the short‐term use of ketorolac is safe and effective in the management of moderate‐to‐severe pain in children. Acta Paediatrica. 2018;107(4):560–7.
25.
Maslin B, Lipana L, Roth B, Kodumudi G, Vadivelu N. Safety Considerations in the Use of Ketorolac for Postoperative Pain. Current Drug Safety. 2017;12(1):67–73.
26.
Butcher B, Hutchings E, Fazekas B, Clark K, Rowett D, Currow D. Opioid-sparing effects of ketorolac in palliative care patients receiving opioids for chronic cancer-related pain: A systematic literature review. Palliative Medicine. 2022;36(1):71–80.
27.
Vonkeman HE, van de Laar MAFJ. Nonsteroidal Anti-Inflammatory Drugs: Adverse Effects and Their Prevention. Seminars in Arthritis and Rheumatism. 2010;39(4):294–312.
28.
Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly. Aging and disease. 2018;9(1):143.
29.
Ribeiro H, Rodrigues I, Napoleão L, Lira L, Marques D, Veríssimo M, et al. Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features. Biomedicine & Pharmacotherapy. 2022;150:112958.
30.
Cao YL. Characteristics and clinical outcome of nonsteroidal anti-inflammatory drug-induced acute hepato-nephrotoxicity among Chinese patients. World Journal of Gastroenterology. 2014;20(38):13956.
31.
Mariano F, Cogno C, Giaretta F, Deambrosis I, Pozza S, Berardino M, et al. Urinary protein profiles in ketorolac-associated acute kidney injury in patients undergoing orthopedic day surgery. International Journal of Nephrology and Renovascular Disease. Volume 10:269–74.
32.
Othman AI, Abdel-Ghaffar A, Mahmoud AM. Ketorolac- and warfarin-induced renal toxicity: ultrastructural and biochemical study. The Journal of Basic and Applied Zoology. 2019;80(1).
33.
Bories M, Bacle A, Gilardi H, Le Corre P. Risk of acute kidney injury by initiation of non-steroidal anti-inflammatory drugs in hospitalised patients treated with diuretics and renin–angiotensin–aldosterone system inhibitors. European Journal of Hospital Pharmacy. 2022;29(6):359–61.
34.
Forestell B, Sabbineni M, Sharif S, Chao J, Eltorki M. Comparative Effectiveness of Ketorolac Dosing Strategies for Emergency Department Patients With Acute Pain. Annals of Emergency Medicine. 2023;82(5):615–23.
35.
Jota Baptista CV, Faustino-Rocha AI, Oliveira PA. Animal Models in Pharmacology: A Brief History Awarding the Nobel Prizes for Physiology or Medicine. Pharmacology. 2021;106(7–8):356–68.
36.
Kalas MA, Chavez L, Leon M, Taweesedt PT, Surani S. Abnormal liver enzymes: A review for clinicians. World Journal of Hepatology. 2021;13(11):1688–98.
37.
McGill MR. The past and present of serum aminotransferases and the future of liver injury biomarkers. EXCLI J. 2016;15:817–28.
38.
Youssef EM, Wu GY. Subnormal Serum Liver Enzyme Levels: A Review of Pathophysiology and Clinical Significance. Journal of Clinical and Translational Hepatology. 2024;12(4):428–35.
39.
Sriuttha P, Sirichanchuen B, Permsuwan U. Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials. International Journal of Hepatology. 2018;2018:1–13.
40.
Rostom A, Goldkind L, Laine L. Nonsteroidal Anti-Inflammatory Drugs and Hepatic Toxicity: A Systematic Review of Randomized Controlled Trials in Arthritis Patients. Clinical Gastroenterology and Hepatology. 2005;3(5):489–98.
41.
Lapeyre‐Mestre M, De Castro AMR, Bareille M, Pozo JG del, Requejo AA, Arias LM, et al. Non‐steroidal anti‐inflammatory drug‐related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. Fundamental & Clinical Pharmacology. 2006;20(4):391–5.
42.
Rivera-Espinosa L, Muriel P, Ordaz Gallo M, Pérez-Urizar J, Palma-Aguirre A, Castañeda-Hernández G. Ketorolac pharmacokinetics in experimental cirrhosis by bile duct ligation in the rat. Annals of Hepatology. 2003;2(4):175–81.
43.
Lu W, Cheng F, Jiang J, Zhang C, Deng X, Xu Z, et al. FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach. Scientific Reports. 5(1).
44.
Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World Journal of Gastroenterology. 2010;16(45):5651.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
